Harnessing local and systemic immunity for vaccines against tuberculosis

Mucosal Immunology

Volumn 7, Issue 1, 2014, Pages 20-26

  Beverley, P C L ^a   Sridhar, S ^b   Lalvani, A ^b   Tchilian, E Z ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BCG VACCINE; MVA 85 A; RECOMBINANT VACCINIA VIRUS BOOSTER VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

BACTERIAL GROWTH; BCG VACCINATION; EXPERIMENTAL ANIMAL; HUMAN; IMMUNITY; INNATE IMMUNITY; LOWER RESPIRATORY TRACT; LUNG LAVAGE; LUNG PARENCHYMA; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANIMALS; BCG VACCINE; HUMANS; IMMUNITY, INNATE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84890904145     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.99     Document Type: Review

References (84)

1. Bishai,W., Sullivan, Z., Bloom, B.R. & Andersen, P. Bettering BCG: a tough task for a TB vaccine?. Nat. Med 19, 410-411 (2013).
2. Tameris, M.D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028 (2013).
3. Tameris, M. et al. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis (Edinb) 93, 143-149 (2013).
4. Lalvani, A., Sridhar, S. & Fordham von Reyn, C. Tuberculosis vaccines: time to reset the paradigm? Thorax, doi:10.1136/thoraxjnl-2013-203456 2013 (e-pub ahead of print).
5. Tchilian, E.Z. et al. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85 A against murine tuberculosis. Infect. Immun 77, 622-631 (2009).
6. Williams, A. et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 85, 29-38 (2005).
7. Vordermeier, H.M. et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun 77, 3364-3373 (2009).
8. Verreck, F.A. et al. MVA.85 A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4, e5264 (2009).
9. Sharpe, S.A. et al. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin. Vaccine Immunol 17, 1170-1182 (2010).
10. McShane,H. et al. Recombinantmodified vaccinia virus Ankara expressing antigen 85 A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med 10, 1240-1244 (2004).
11. Tatsis, N., Lin, S.W., Harris-McCoy, K., Garber, D.A., Feinberg, M.B. & Ertl, H.C. Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. Virology 367, 156-167 (2007).
12. Lin, P.L. et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest 122, 303-314 (2012).
13. Lindenstrom, T. et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory Tcells. J. Immunol 182, 8047-8055 (2009).
14. Lindenstrom, T., Knudsen, N.P., Agger, E.M. & Andersen, P. Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1- IL-2- secreting central memory cells. J. Immunol 190, 6311-6319 (2013).
15. Khader, S.A. et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol 8, 369-377 (2007).
16. Vordermeier, H.M. et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112, 461-470 (2004).
17. Ernst, J.D. The immunological life cycle of tuberculosis. Nat. Rev. Immunol. 12, 581-591 (2012).
18. Shaler, C.R., Horvath, C., Lai, R. & Xing, Z. Understanding delayed T-cell priming, lung recruitment, and airway luminal T-cell responses in host defense against pulmonary tuberculosis. Clin. Dev. Immunol 2012, 628293 (2012).
19. Reiley, W.W. et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl. Acad. Sci. USA 105, 10961-10966 (2008).
20. Cooper, A.M. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27, 393-422 (2009).
21. Horvath, C.N., Shaler, C.R., Jeyanathan, M., Zganiacz, A. & Xing, Z. Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells. Mucosal. Immunol 5, 420-431 (2012).
22. Tchilian, E.Z. et al. Simultaneous immunization against tuberculosis. PLoS One 6, e27477 (2011).
23. Winslow, G.M., Cooper, A., Reiley, W., Chatterjee, M. & Woodland, D.L. Early T-cell responses in tuberculosis immunity. Immunol. Rev. 225, 284-299 (2008).
24. Connor, L.M. et al. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur. J. Immunol 40, 2482-2492 (2010).
25. Jiang, X., Clark, R.A., Liu, L.,Wagers, A.J., Fuhlbrigge, R.C. & Kupper, T.S. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 483, 227-231 (2012).
26. Wakim, L.M., Gupta, N., Mintern, J.D. & Villadangos, J.A. Enhanced survival of lung tissue-residentmemory CD8(+) Tcells during infection with influenza virus due to selective expression of IFITM3. Nat. Immunol 14, 238-245 (2013).
27. Liang, S., Mozdzanowska, K., Palladino, G. & Gerhard,W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol 152, 1653-1661 (1994).
28. Hogan, R.J. et al. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol 166, 1813-1822 (2001).
29. Purwar, R., Campbell, J., Murphy, G., Richards, W.G., Clark, R.A. & Kupper, T.S. Resident memory Tcells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS One 6, e16245 (2011).
30. Walrath, J., Zukowski, L., Krywiak, A. & Silver, R.F. Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am. J. Respir. Cell. Mol. Biol 33, 48-55 (2005).
31. Ronan, E.O., Lee, L.N., Tchilian, E.Z. & Beverley, P.C. Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine. Vaccine 28, 5179-5184 (2010).
32. Song, K. et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc. Natl. Acad. Sci. USA 107, 22213-22218 (2010).
33. Bourdin, A., Gras, D., Vachier, I. & Chanez, P. Upper airway x 1: allergic rhinitis and asthma: united disease through epithelial cells. Thorax 64, 999-1004 (2009).
34. Hurst, J.R. Upper airway. 3: sinonasal involvement in chronic obstructive pulmonary disease. Thorax 65, 85-90 (2010).
35. Wang, J. et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol 173, 6357-6365 (2004).
36. Santosuosso, M., Zhang, X., McCormick, S., Wang, J., Hitt, M. & Xing, Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 Tcells within the airway lumen. J. Immunol 174, 7986-7994 (2005).
37. Forbes, E.K. et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol 181, 4955-4964 (2008).
38. Goonetilleke, N.P., McShane, H., Hannan, C.M., Anderson, R.J., Brookes, R.H. & Hill, A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol 171, 1602-1609 (2003).
39. Ronan, E.O., Lee, L.N., Beverley, P.C. & Tchilian, E.Z. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS One 4, e8235 (2009).
40. Santosuosso, M., McCormick, S., Zhang, X., Zganiacz, A. & Xing, Z. Intranasal boosting with an adenovirus-vectored vaccinemarkedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun 74, 4634-4643 (2006).
41. Lee, L.N. et al.CXCR6 is amarker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect. Immun 79, 3328-3337 (2011).
42. Jeyanathan,M. et al. Murine airway luminal anti-tuberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am. J. Respir. Crit. Care Med 181, 862-872 (2010).
43. Xu, B. et al. Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways. J. Exp. Med 197, 1255-1267 (2003).
44. Moyron-Quiroz, J.E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med 10, 927-934 (2004).
45. Gopal, R. et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol 6, 972-984 (2013).
46. Chen, X. et al. Regulation of TB vaccine-induced airway luminal T cells by respiratory exposure to endotoxin. PLoS One 7, e41666 (2012).
47. Schwander, S.K. et al. Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community. J. Immunol 165, 1479-1485 (2000).
48. Schwander, S.K. et al. T lymphocytic and immature macrophage alveolitis in active pulmonary tuberculosis. J. Infect. Dis 173, 1267-1272 (1996).
49. Boras, Z., Juretic, A., Gagro, A. & Pavelic, L. Cytokine profile of t lymphocytes from peripheral blood and bronchoalveolar lavage fluid in patients with active pulmonary tuberculosis. Scand. J. Immunol 65, 257-264 (2007).
50. Larsen, M.H. et al. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27, 4709-4717 (2009).
51. Chen, C.Y. et al. A critical role for CD8 Tcells in a nonhuman primate model of tuberculosis. PLoS Pathog 5, e1000392 (2009).
52. Langermans, J.A. et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23, 2740-2750 (2005).
53. Lai, X. et al. Immune biology of macaque lymphocyte populations during mycobacterial infection. Clin. Exp. Immunol 133, 182-192 (2003).
54. Barclay,W.R. et al. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107, 351-358 (1973).
55. White, A.D. et al. An evaluation of the safety and immunogenicity of a candidate TB vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin. Vaccine. Immunol 20, 663-672 (2013).
56. Whelan, A. et al. Immunogenicity comparison of the intradermal or endobronchial boosting of BCG vaccinates with Ad5-85 A. Vaccine 30, 6294-6300 (2012).
57. Antonelli, L.R. et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest 120, 1674-1682 (2010).
58. Cooper, A.M., Mayer-Barber, K.D. & Sher, A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol 4, 252-260 (2011).
59. Potian, J.A., Rafi, W., Bhatt, K., McBride, A., Gause, W.C. & Salgame, P. Preexisting helminth infection induces inhibition of innate pulmonary antituberculosis defense by engaging the IL-4 receptor pathway. J Exp Med 208, 1863-1874 (2011).
60. Aranday Cortes, E., Kaveh, D., Nunez-Garcia, J., Hogarth, P.J. & Vordermeier, H.M. Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice. PLoS One 5, e11319 (2010).
61. Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2- dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 109, 17537-17542 (2012).
62. Ivanov, I.I. & Littman, D.R. Modulation of immune homeostasis by commensal bacteria. Curr. Opin. Microbiol. 14, 106-114 (2011).
63. Juarez, E., Nunez, C., Sada, E., Ellner, J.J., Schwander, S.K. & Torres, M. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir. Res 11, 2 (2010).
64. Nguyen, H.A., Rajaram, M.V., Meyer, D.A. & Schlesinger, L.S. Pulmonary surfactant protein A and surfactant lipids upregulate IRAK-M, a negative regulator of TLR-mediated inflammation in human macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol 303, L608-L616 (2012).
65. Henning, L.N., Azad, A.K., Parsa, K.V., Crowther, J.E., Tridandapani, S. & Schlesinger, L.S. Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages. J. Immunol. 180, 7847-7858 (2008).
66. Schwander, S. & Dheda, K. Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am. J. Respir. Crit. Care Med 183, 696-707 (2011).
67. Jeyanathan, M. et al. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunol 6, 612-625 (2013).
68. Bennekov, T., Dietrich, J., Rosenkrands, I., Stryhn, A., Doherty, T.M. & Andersen, P. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur. J. Immunol 36, 3346-3355 (2006).
69. Hansen, S.G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013).
70. Tchilian, E., Ahuja, D., Hey, A., Jiang, S. & Beverley, P. Immunization with different formulations of Mycobacterium tuberculosis antigen 85 A induces immune responses with different specificity and protective efficacy. Vaccine 31, 4624-4631 (2013).
71. Brennan, M.J. et al. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 30, 2811-2823 (2012).
72. Woodland, D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25, 98-104 (2004).
73. Draper, S.J. & Heeney, J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol 8, 62-73 (2010).
74. Robinson, H.L. & Amara, R.R. Tcell vaccines for microbial infections. Nat. Med 11, S25-S32 (2005).
75. Hansen, S.G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
76. Aagaard, C. et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17, 189-194 (2011).
77. Reed, S.G. et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 106, 2301-2306 (2009).
78. Billeskov, R., Elvang, T.T., Andersen, P.L. & Dietrich, J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 7, e39909 (2012).
79. Xing, Z., McFarland, C.T., Sallenave, J.M., Izzo, A., Wang, J. & McMurray, D.N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 4, e5856 (2009).
80. Cohn, M.L., Davis, C.L. & Middlebrook, G. Airborne immunization against tuberculosis. Science 128, 1282-1283 (1958).
81. Buddle,B.M.et al. Protection of cattle frombovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res. Vet. Sci 59, 10-16 (1995).
82. Rosenthal, S.R., McEnery, J.T. & Raisys, N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J. Asthma Res 5, 309-323 (1968).
83. Cutts, F.T., Clements, C.J. & Bennett, J.V. Alternative routes of measles immunization: a review. Biologicals 25, 323-338 (1997).
84. Xing, Z. & Charters, T.J. Heterologous boost vaccines for bacillus Calmette-Guerin prime immunization against tuberculosis. Expert Rev. Vaccines 6, 539-546 (2007).